Product Data Sheet



Sarafotoxin S6c

Cat. No.: HY-102029 CAS No.: 121695-87-2 Molecular Formula: $C_{103}H_{147}N_{27}O_{37}S_5$

Molecular Weight: 2515.75

Sequence Shortening: CTCNDMTDEECLNFCHQDVIW (Disulfide bridge: Cys1-Cys15; Cys3-Cys11)

Target: **Endothelin Receptor** Pathway: GPCR/G Protein

Storage: Sealed storage, away from moisture and light, under nitrogen

> Powder -80°C 2 years 1 year

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture

and light, under nitrogen)

BIOLOGICAL ACTIVITY

Description	Sarafotoxin S6c (SRTX-c) is a potent endothelin-B receptor agonist. Sarafotoxin S6c can cause vasoconstriction in both endothelium-intact and endothelium-denuded vessels ^[1] .	
IC ₅₀ & Target	Endothelin-B receptor ^[1]	
In Vivo	Sarafotoxin S6c can cause vasoconstriction in both endothelium-intact and endothelium-denuded vessels ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Male Wister rats, exposed to 10% O $_2$ [chronic hypoxic (CH) rats] or room air (control rats) for 2 weeks $^{[1]}$
	Dosage:	1 pM-1 mM
	Administration:	
	Result:	Chronic hypoxia had effect on the sensitivity of the main pulmonary arteries to SCS6c, and small vasoconstrictor responses to were evident. Caused vasoconstriction with a maximum response 30% of that to ET-1 in both endothelium-intact and endothelium-denuded vessels.

REFERENCES

[1]. MacLean MR, et al. Effects of pulmonary hypertension on vasoconstrictor responses to endothelin-1 and sarafotoxin S6C and on inherent tone in rat pulmonary arteries. J Cardiovasc Pharmacol. 1995 Nov;26(5):822-30.

Page 1 of 2 www.MedChemExpress.com $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com